Skip to main content

Table 2 Efficacy assessments

From: Pazopanib versus sunitinib in Chinese patients with locally advanced or metastatic renal cell carcinoma: pooled subgroup analysis from the randomized, COMPARZ studies

ParameterInvestigator assessmentIRC assessment
PazopanibSunitinibPazopanibSunitinib
Number of patients109100109100
Median PFS (1st quartile, 3rd quartile) months13.9 (8.0, 20.2)14.3 (5.6, 27.7)8.3 (5.5, 19.3)8.3 (4.1, 24.7)
HR (95% CI)1.17 (0.792–1.727)
P = 0.4381
0.99 (0.6760–1.4580)
P = 0.9629
ORR, %41233520
P = 0.0052P = 0.0203
  1. CI Confidence interval, HR Hazard ratio, IRC Independent review committee, ORR Overall response rate, PFS Progression-free survival